Key Takeaways:
- Cauldron Ferm has closed a $13.25 million Series A2 round led by Main Sequence Ventures, bringing total funding to $26 million
- The round includes participation from Horizons Ventures, SOSV, and NGS Super
- Cauldron Ferm has been named to Fast Company's 2026 list of the World's Most Innovative Companies
- The company is the first to demonstrate continuous fermentation for synthetic biology strains at 10,000-liter industrial scale
- New capital will support retrofitting existing facilities and expanding demo-scale operations in Australia and the U.S.
Cauldron Ferm Closes $13.25M Series A2 Round
Cauldron Ferm, an advanced biomanufacturing company, has announced the closing of a $13.25 million Series A2 priced funding round, bringing its total capital raised to $26 million. The round was led by Main Sequence Ventures, with participation from Horizons Ventures, SOSV, and NGS Super, one of Australia's largest pension funds.
Alongside the funding announcement, Cauldron Ferm has been named to Fast Company's 2026 list of the World's Most Innovative Companies.
What Is Hyper-Fermentation?
At the core of Cauldron Ferm's offering is its proprietary continuous “hyper-fermentation” platform. Biomanufacturing relies on living cells — specifically bio-engineered microbes — that convert simple inputs such as sugars into valuable products. Cauldron's technology keeps these microbes in a sustained, highly productive steady state, allowing processes to run continuously over extended periods.
